Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


U.S., China discuss medicine

This article was originally published in The Tan Sheet

Executive Summary

The signing of a memorandum of understanding "to foster collaboration between scientists in both countries" in researching integrative and traditional Chinese medicine kicks-off a two-day roundtable discussion of traditional Chinese medicine, according to a June 16 release. Roundtable participants, including Health and Human Services Secretary Mike Leavitt, NIH scientists and the Chinese State Administration led by Vice Minister of Health Wang Guoqiang, discussed criteria to evaluate traditional Chinese medicine practices, the synthesis of Western and traditional Chinese medicine and the application of modern scientific tools to traditional Chinese medicine. In October 2007, Coca-Cola opened a research center in Beijing focused on locally sourced traditional Chinese herbs and formulas that the food and beverage giant plans to use for products it will offer worldwide (1"The Tan Sheet" Nov. 5, 2007, p. 14)...

You may also be interested in...

Coca-Cola Sets Up Beijing Roots To Develop Chinese Herbal Products

Coca-Cola preceded the opening of its first research center in China with extensive research on locally sourced traditional Chinese herbs and formulas, which it plans to use for products it will offer worldwide, the Atlanta-based beverage giant said Oct. 14

Long Hot Summer For Novel Drug Reviews Forecast At US FDA

Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.

Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza

The latest drug development news and highlights from our US FDA Performance Tracker.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts